ASX:PERPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals

PERCHERON THERAPEUTICS ORD

$0.004

Day Range

$0.004 - $0.005

52 Week Range

$0.004 - $0.012

Volume

0.00

Avg Volume (10D)

1.69M

Market Cap

$5.04M

Price Chart

Market Statistics

Open$0.004

Previous Close$0.004

Day High$0.005

Day Low$0.004

52 Week High$0.012

52 Week Low$0.004

Valuation

Market Cap5.04M

Shares Outstanding1.26B

Price to Book0.64

Trading Activity

Volume0.00

Value Traded0.00

Bid$0.004 × 20,715,508

Ask$0.005 × 4,828,032

Performance

1 Day0.00%

5 Day-11.11%

13 Week-50.59%

52 Week-65.00%

YTD-53.33%

Technical Indicators

RSI (14)40.16

50-Day SMA$0.006

200-Day SMA$0.008

Percheron Therapeutics acquires worldwide licence to commercialise HMBD-002 cancer therapy

Percheron Therapeutics (ASX: PER) has acquired a worldwide exclusive license from Singapore-based Hummingbird Bioscience for monoclonal antibody therapy HMBD-002 to treat a range of cancer indications. The company will pay Hummingbird an upfront consideration of $4.6 million plus milestone payments of as much as $443m and royalties on net sales of the commercial product. Percheron […]

1 min read

Imelda Cotton

Biotechnology

Percheron Therapeutics completes toxicology study for avicursen ahead of US FDA discussions

Australian biotechnology company Percheron Therapeutics (ASX: PER) has completed a nine-month toxicology study in non-human primates for its lead program, avicursen. Avicursen is an antisense oligonucleotide that targets the CD49d biomarker. The study, which commenced in March 2023, concluded its final dosing on schedule in December. Recovery phase The majority of subjects in the study […]

1 min read

Imelda Cotton